FDA clears Misonix's 3-in-1 ultrasonic surgery system

FDA Building
Misonix plans to begin commercialization in July and hopes the Nexus system will serve as a base for future solutions and add-ons. (FDA)

Ultrasonic surgical tool manufacturer Misonix has received clearance from the FDA for its new Nexus system, which combines the features of the company’s three existing handheld offerings into one platform.

That includes BoneScalpel, a precision, oscillating tool designed for millimeter-wide cuts in bone while sparing the surrounding soft tissue. Meanwhile, its SonicOne attachment provides a debridement tool for cleaning wounds and removing damaged tissue or bacterial biofilms during surgery.

The SonaStar ultrasonic aspirator is used to remove more-targeted tissues, such as tumors. It also includes bone-sculpting tips and a range of deep-access and laparoscopic probes.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Farmingdale, New York-based Misonix plans to begin its U.S. commercialization of the combined Nexus platform in July and hopes it will serve as a base for future solutions. It also includes increased power, a touchscreen display and RF capabilities for use in general surgery procedures.

RELATED: TransEnterix granted CE mark for ultrasonic robotic surgery tech

“Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets,” Misonix President and CEO Stavros Vizirgianakis said in a statement.

“Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties,” Vizirgianakis added.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.